VE202 is a rationally-defined bacterial consortium candidate being developed for the treatment of inflammatory bowel disease in partnership with Janssen Research & Development, LLC. VE202 consists of clonal human commensal bacteria strains selected for their ability to impact the number and activity of regulatory T cells in the gut mucosa and manufactured under GMP conditions. The foundational research underlying VE202 led by Vedanta Biosciences co-founder Kenya Honda, M.D., Ph.D. of Keio University School of Medicine was published in Science and two additional publications in Nature (Atarashi et al. 2013; Furusawa et al. 2013)
A Phase 1 clinical study of VE202 in healthy volunteers was initiated in Q4 2018 by Janssen Research & Development. As part of its license agreement with Janssen, Vedanta is eligible for development and commercialization milestones of up to a total of $339 million in addition to royalty payments.